Thermo Fisher Collaborates on Major Proteomics Biobank Initiative in Singapore's PRECISE-SG100K Project

- Thermo Fisher Scientific collaborates with PRECISE to establish a large-scale proteomics biobank initiative in Singapore.
- The partnership supports the PRECISE-SG100K project, one of Asia's largest population health studies.
- Thermo Fisher will employ advanced technology to enhance health research and personalized medicine development.
Thermo Fisher Scientific (NYSE:TMO) announces a strategic collaboration with Precision Health Research, Singapore (PRECISE), aimed at significantly enhancing health research capabilities in the region. This partnership develops the PRECISE-SG100K project, recognized as one of Asia's extensive longitudinal population health studies, focusing on proteomics data collection and analysis.
Revolutionizing Population Health Research
Through this collaboration, Thermo Fisher intends to deploy its advanced platforms, including the Olink PEA and the Orbitrap Astral mass spectrometry system. The initiative's primary goal is to forge a regulatory-grade biobank infrastructure that supports large-scale health research. This infrastructure is expected to play a pivotal role in bolstering scientific inquiry surrounding population health and advancing personalized medicine strategies in Singapore and beyond.
Focus on Proteomics and Personalized Medicine
By integrating complementary technologies in proteomics, Thermo Fisher aims not only to enhance research capacity but also to facilitate better understanding of health outcomes across diverse populations. This strategic move aligns with global trends toward precision health measures that cater to individual needs, promising to transform how health sciences address the unique health challenges faced by populations.
Commitment to Advancing Health Solutions
This collaboration highlights Thermo Fisher's commitment to being at the forefront of innovation in life sciences. As the project progresses, it anticipates nurturing a collaborative environment between researchers and healthcare professionals, thereby enhancing the delivery of tailored health solutions that could lead to significant advancements in public health initiatives.
Related Cashu News

Bristol-Myers Squibb's Reclassification Enhances Growth Potential in Defensive Investment Strategy
Bristol-Myers Squibb Company (Ticker: BMY) undergoes a key reclassification across the Russell indexes, marking a transformative moment for the company. Moving to the Russell 1000 Defensive and Russel…

Vertex Pharmaceuticals' Casgevy Gains FDA Approval for Expanded Sickle Cell Disease Treatment Options
Vertex Pharmaceuticals (Ticker: VRTX) receives a significant boost in its ongoing battle against sickle cell disease with the recent FDA approval of an expanded label for its gene therapy product, Cas…

Gilead Sciences Gains FDA Approval for Trodelvy in First-Line Triple-Negative Breast Cancer Treatment
Gilead Sciences (Ticker: GILD) makes significant strides in oncology therapy with the recent approval of its drug Trodelvy for patients with unresectable or metastatic triple-negative breast cancer. T…

Merck Advances HIV Treatment and Faces Regulatory Scrutiny Amidst Market Success
Merck & Co. (Ticker: MRK) has recently made significant strides in the pharmaceutical landscape, particularly with its advancements in HIV treatment. The company's innovative drug, IDVYNSO, has receiv…

